New Oncology Drugs/Indications Approved by the FDA.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 2, p. 105
- Publication type:
- Article
Works matching IS 21641153 AND DT 2021 AND VI 11 AND IP 2
Results: 8
1
2
Overcoming Resistance: Antibiotic Guidance for Multidrug-Resistant Febrile Neutropenia in Patients with Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 2, p. 95
- By:
- Publication type:
- Article
3
Watch Out for a Vaccine Patent Heist: The left wants Biden to force drug companies to give away their IP.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 2, p. 93
- Publication type:
- Article
4
Biomarker-Driven Targeted Therapies in Solid Tumor Malignancies.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 2, p. 84
- By:
- Publication type:
- Article
5
Comparison of Direct Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Obese or Overweight Patients: A Retrospective Analysis.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 2, p. 77
- By:
- Publication type:
- Article
6
Concise Reviews of Studies Relevant to Hematology Oncology Pharmacy.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 2, p. 74
- By:
- Publication type:
- Article
7
Assessment of High-Dose Methotrexate Management Guideline in Adults with Cancer at an Academic Medical Center.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 2, p. 69
- By:
- Publication type:
- Article
8
Facial Edema Preceding Acute Renal Injury Linked to Pemetrexed Therapy in a Patient with Lung Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2021, v. 11, n. 2, p. 66
- By:
- Publication type:
- Article